Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
We currently expect the recently implemented tariffs globally to increase our 2025 cost of sales by approximately 1% of revenue.
the situation of tariffs and geopolitics disrupting supply chains, I think that's not over.
In theory, tariffs should not have huge impact on the innovation biopharma ecosystem, mostly because of the low cost of goods sold relative to other industries like hardcore manufacturing.
we expect to absorb the impact of tariffs currently in place, primarily in Europe and China.
Our current assessment of 2025 tariff costs, net of mitigation is around $500 million, with approximately $125 million already incurred in the first half of the year.
We estimate the indirect effect of tariffs lowered our earnings per share by more than $0.10 in the quarter.
We have updated our 2025 tariff impact to be approximately $75 million for the full year, which includes $15 million in Q2 and an estimated $60 million in the second half of 2025.
Tariffs did not have a significant impact on our financial results through the end of the second quarter, but we expect to see an impact in the back half of the year if current tariffs remain in place.
During our Q1 call, we indicated a potential impact of tariffs of approximately $5,000 per unit that could hit in the latter part of Q4. At this time, we now expect any impact from tariffs in Q4 to be lower, which will help offset the cost of elevated incentives.
In Q2, tariffs impacted our business by $27 million. For Q3, we currently expect a negative impact of about $35 million, or about $0.04 per share, which is included in our guidance.